Answers are grounded in this paper and cite their sources.
Analysis of BCG failure types influences post-BCG treatment outcomes in high-risk bladder cancer, suggesting tailored approaches.
Gemcitabine/docetaxel demonstrated meaningful activity across all BCG failure types, with late BCG relapsing patients achieving the most favourable outcomes and refractory disease showing the poorest control. These findings underscore the clinical relevance of distinguishing BCG failure subtypes when selecting candidates for post-BCG intravesical gemcitabine/docetaxel and designing future prospective trials.
No takes yet. Share an insight, caveat, or question.
Scilipoti et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: